US2011311547A1PendingUtilityA1

Arthritis Treatment

56
Assignee: SIMARD JOHNPriority: Jun 18, 2010Filed: Jun 17, 2011Published: Dec 22, 2011
Est. expiryJun 18, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:John Simard
A61P 29/00A61P 27/02A61P 19/00A61P 19/02C07K 16/245A61K 9/0048A61K 39/395A61K 9/0019A61K 2039/505A61K 39/39533
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis.

Claims

exact text as granted — not AI-modified
1 . A method for treating an inflammatory pathology associated with arthritis in a human subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-IL-1α antibody effective to reduce at least one symptom of the inflammatory pathology in the subject. 
     
     
         2 . The method of  claim 1 , wherein the at least one symptom is joint inflammation. 
     
     
         3 . The method of  claim 2 , wherein the joint inflammation is in the wrist of the subject. 
     
     
         4 . The method of  claim 2 , wherein the joint inflammation is in the shoulder of the subject. 
     
     
         5 . The method of  claim 1 , wherein the at least one symptom is inflammation of the eye. 
     
     
         6 . The method of  claim 5 , wherein the inflammation is uveitis. 
     
     
         7 . The method of  claim 1 , wherein the anti-IL-1α antibody is a monoclonal antibody. 
     
     
         8 . The method of  claim 7 , wherein the monoclonal antibody is an IgG1. 
     
     
         9 . The method of  claim 7 , wherein the monoclonal antibody comprises a complementarity determining region of MABp1. 
     
     
         10 . The method of  claim 7 , wherein the monoclonal antibody is MABp1. 
     
     
         11 . The method of  claim 1 , wherein the pharmaceutical composition is administered by injection. 
     
     
         12 . The method of  claim 11 , wherein the pharmaceutical composition is injected into an inflamed joint. 
     
     
         13 . The method of  claim 5 , wherein the pharmaceutical composition is administered to the eye topically. 
     
     
         14 . The method of  claim 5 , wherein the pharmaceutical composition is administered to the eye by injection. 
     
     
         15 . The method of  claim 1 , wherein the amount of the anti-IL-1α antibody effective to reduce at least one symptom of the inflammatory pathology in the subject is sufficient to raise the subject's peripheral blood concentration of anti-IL-1α antibody to at least 4 micrograms/ml. 
     
     
         16 . A method of inducing monocyte vacuolization in a subject, the method comprising administering to the subject an amount of an anti-IL-1α antibody effective to induce monocyte vacuolization in the subject. 
     
     
         17 . The method of  claim 16 , wherein the subject has arthritis. 
     
     
         18 . The method of  claim 16 , wherein the anti-IL-1α antibody is a monoclonal antibody. 
     
     
         19 . The method of  claim 18 , wherein the monoclonal antibody is an IgG1. 
     
     
         20 . The method of  claim 18 , wherein the monoclonal antibody comprises a complementarity-determining region of MABp1. 
     
     
         21 . The method of  claim 20 , wherein the monoclonal antibody is MABp1. 
     
     
         22 . The method of  claim 16 , wherein the amount of the anti-IL-1α antibody administered to the subject is sufficient to raise the subject's peripheral blood concentration of anti-IL-1α antibody to at least 4 micrograms/ml.

Join the waitlist — get patent alerts

Track US2011311547A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.